The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes

被引:8
|
作者
Ceriello, Antonio [1 ,2 ]
De Nigris, Valeria [1 ]
Pujadas, Gemma [1 ]
La Sala, Lucia [1 ,2 ,3 ]
Bonfigli, Anna Rita [4 ]
Testa, Roberto [5 ]
Uccellatore, Annachiara [3 ]
Genovese, Stefano [3 ]
机构
[1] IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain
[2] Hosp Clin Barcelona, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
[3] IRCCS Grp Multimed, Dept Cardiovasc & Metab Dis, Sesto San Giovanni, MI, Italy
[4] INRCA Ancona, Sci Direct, Ancona, Italy
[5] INRCA IRCCS Natl Inst, Expt Models Clin Pathol, Ancona, Italy
关键词
Type; 1; diabetes; GLP-1; Endothelial function; Oxidative stress; Metabolic memory; GLUCAGON-LIKE PEPTIDE-1; OXIDATIVE STRESS; DYSFUNCTION; VASODILATATION; ACTIVATION; MELLITUS; MARKERS; CELLS;
D O I
10.1016/j.diabres.2016.01.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To test the effect of normoglycemia and glucagon-like peptide-1 (GLP-1), alone or in combination, on the possible normalization of endothelial function in type 1 diabetes. Methods: Fifteen people with type 1 diabetes participated in three experiments: reaching and maintaining normoglycemia for 4 h; reaching and maintaining hyperglycemia plus GLP-1 infusion for 4 h; and reaching and maintaining normoglycemia for 4 h with simultaneous infusion of GLP-1. Results: Both normoglycemia and GLP-1 infusion restored endothelial function and decreased and plasma 8-iso prostaglandin F2 alpha levels. However, only the combination of normoglycemia and GLP-1 was able to normalize endothelial function. Conclusions: This study confirms that long-lasting hyperglycemia in type 1 diabetes induces a permanent alteration which contributes to maintaining endothelial dysfunction even when glycemia is normalized, and that in the presence of normoglycemia, GLP-1 can contribute to normalizing endothelial function. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:64 / 68
页数:5
相关论文
共 50 条
  • [31] Long acting GLP-1 for the treatment of type 2 diabetes
    Reichstetter, Sandra
    Castillo, Gerardo
    Perfetti, Riccardo
    Leahy, Mark
    Bolotin, Elijah
    DIABETES, 2007, 56 : A144 - A144
  • [32] GLP-1 analogues for treatment of type 2 diabetes in adolescents
    Veyder-Malberg, Caroline
    Furthner, Dieter
    Dalus, Christopher
    Maruszczak, Katharina
    Schneider, Anna-Maria
    Weghuber, Daniel
    MONATSSCHRIFT KINDERHEILKUNDE, 2021, 169 (03) : 253 - 257
  • [33] GLP-1: a new approach for type 2 diabetes therapy
    Giorgino, Francesco
    Laviola, Luigi
    Leonardini, Anna
    Natalicchio, Annalisa
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 : S152 - S155
  • [34] GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus
    Dahiya, Lalita
    Kaur, Ramandeep
    Kumar, Rajiv
    Kumar, Manoj
    Palta, Kezia
    CURRENT DIABETES REVIEWS, 2020, 16 (04) : 279 - 292
  • [35] Determinants of the effectiveness of GLP-1 in type 2 diabetes.
    Toft-Nielsen, MB
    Madsbad, S
    Damholt, MB
    Holst, JJ
    DIABETOLOGIA, 2000, 43 : A147 - A147
  • [36] Renal effects of GLP-1 agonists in type 2 diabetes
    Elbert, Alicia
    Castellaro, Carlos
    Litwak, Leon
    Inserra, Felipe
    Wassermann, Alfredo
    Sinay, Isaac
    MEDICINA-BUENOS AIRES, 2022, 82 (04) : 576 - 590
  • [37] Effectiveness of GLP-1 Analogues in Type 2 Diabetes mellitus
    Schuett, Morten
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (1-2) : 15 - 15
  • [38] Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes
    Levy, JC
    DIABETIC MEDICINE, 2006, 23 : 14 - 19
  • [39] Long acting GLP-1 for the treatment of type I diabetes
    Reichstetter, Sandra
    Castillo, Gerardo
    Medarova, Zdravka
    Moore, Anna
    Perfetti, Riccardo
    Leahy, Mark
    Bolotin, Elijah
    DIABETES, 2007, 56 : A73 - A73
  • [40] Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
    Jeff Unger
    Current Diabetes Reports, 2013, 13 : 663 - 668